| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/08/2006 | EP1632489A1 5-(1,1'-Biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6-trione derivatives, as inhibitors of zinc metallondopeptidases, their preparation and use. |
| 03/08/2006 | EP1632488A1 Cyclic tertiary amine compound |
| 03/08/2006 | EP1632484A1 Thiadiazoline derivative |
| 03/08/2006 | EP1632483A1 Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands |
| 03/08/2006 | EP1632479A2 Piperazine derivatives useful as ccr5 antagonists |
| 03/08/2006 | EP1632477A1 Benzamide derivative or salt thereof |
| 03/08/2006 | EP1632475A1 Sertraline hydrochloride polymorphs |
| 03/08/2006 | EP1632474A1 Sertraline hydrochloride polymorphs |
| 03/08/2006 | EP1632473A1 Sertraline hydrochloride polymorphs |
| 03/08/2006 | EP1632472A1 Sertraline hydrochloride polymorphs |
| 03/08/2006 | EP1632471A1 Racemic and optically pure metabolites of Sibutramine, their preparation, compositions comprising them and their use as Dopamine reuptake inhibitors |
| 03/08/2006 | EP1632470A2 Calcium receptor active molecules |
| 03/08/2006 | EP1632259A2 Anti-angiogene compositions and methods of use |
| 03/08/2006 | EP1632249A1 Osteogenesis-promotion enhancer and method of screening the same |
| 03/08/2006 | EP1632248A1 Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness |
| 03/08/2006 | EP1632246A2 Medicament for local use |
| 03/08/2006 | EP1632244A1 Preventives or remedies for hepatopathy |
| 03/08/2006 | EP1632241A1 Preventive and/or remedy for diseases accompanied by tissue destruction |
| 03/08/2006 | EP1632239A1 Pharmaceutical composition comprising a Pseudomonas lindbergii supernatant and a Bacillus coagulans supernatant and its use |
| 03/08/2006 | EP1632237A2 Compositions comprising drospirenone and a complex between ethinyl-estradiol and a cyclodextrin |
| 03/08/2006 | EP1632236A1 Inhibitors of the anandamide transporter |
| 03/08/2006 | EP1632235A2 Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders |
| 03/08/2006 | EP1632234A2 (S,S)-reboxetine for treating chronic fatigue syndrome |
| 03/08/2006 | EP1632233A1 Transfusion preparation for peripheral intravenous administration and method of stabilizing vitamin b1 |
| 03/08/2006 | EP1632232A1 Salt of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile |
| 03/08/2006 | EP1632231A2 Skin penetration enhancing components |
| 03/08/2006 | EP1632230A1 Neurocyte protective agent |
| 03/08/2006 | EP1632229A1 Medicaments for the treatment of urinary tract disorders comprising anticholinergic agents |
| 03/08/2006 | EP1632228A1 Medicinal composition containing triazole compound |
| 03/08/2006 | EP1632227A1 Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction |
| 03/08/2006 | EP1632226A1 Anti-inflammatory analgesic adhesive patch |
| 03/08/2006 | EP1632224A1 Spill resistant pharmaceutical compositions |
| 03/08/2006 | EP1632137A1 Compositions and processes for water-dispersible phytosterols and phytostanols |
| 03/08/2006 | EP1631823A2 NOVEL REGULATORY MECHANISMS OF NF-kappaB |
| 03/08/2006 | EP1631670A2 Conserved hbv and hcv sequences useful for gene silencing |
| 03/08/2006 | EP1631669A2 Cochleate compositions directed against expression of proteins |
| 03/08/2006 | EP1631659A2 Modulation of the rna interference pathway |
| 03/08/2006 | EP1631594A1 Novel agent for stimulating the release of beta-endorphins, cosmetic and/or dermatological compositions containing same and uses thereof |
| 03/08/2006 | EP1631580A2 Methods for the preparation of dhea derivatives |
| 03/08/2006 | EP1631579A2 17beta-hydroxysteroid dehydrogenase inhibitors |
| 03/08/2006 | EP1631576A2 Stabilized immunomodulatory oligonucleotides |
| 03/08/2006 | EP1631575A1 NEW 3-DECLADINOSYL 9a-N -CARBAMOYL AND 9a-N -THIOCARBAMOYL DERIVATIVES OF 9-DEOX-9-DIHYDRO-9a-AZA-9A-HOMOERYTHROMYCIN A |
| 03/08/2006 | EP1631574A1 Colchicoside analogues |
| 03/08/2006 | EP1631567A2 Heterocyclic n-aryl carboxamides as cytokine inhibitors |
| 03/08/2006 | EP1631562A1 Chromene derivatives as anti-inflammatory agents |
| 03/08/2006 | EP1631560A2 C-fms kinase inhibitors |
| 03/08/2006 | EP1631559A2 Il-8 receptor antagonists |
| 03/08/2006 | EP1631558A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
| 03/08/2006 | EP1631556A1 Pharmaceutical composition comprising valsartan |
| 03/08/2006 | EP1631554A2 Nitrogen-containing heteroaryl derivatives for the treatment of hcv-infection |
| 03/08/2006 | EP1631548A2 Inhibitors of akt activity |
| 03/08/2006 | EP1631543A1 Treatment of lung cancer with active vitamin d compounds in combination with other treatments |
| 03/08/2006 | EP1631542A1 Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof |
| 03/08/2006 | EP1631373A1 Micropellets, method for the production thereof, and use thereof |
| 03/08/2006 | EP1631355A1 Piperidinyl prostaglandin e analogs |
| 03/08/2006 | EP1631331A1 A bioabsorbable delivery system |
| 03/08/2006 | EP1631307A1 Methods to mobilize progenitor/stem cells |
| 03/08/2006 | EP1631304A1 Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care |
| 03/08/2006 | EP1631302A1 Migraine remedy |
| 03/08/2006 | EP1631301A1 Combination chemotherapy comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex |
| 03/08/2006 | EP1631300A2 High molecular weight polymers, devices and method for making and using same |
| 03/08/2006 | EP1631299A2 Methods and compositions to treat myocardial conditions |
| 03/08/2006 | EP1631298A1 Glycosaminoglycans for treating emotional dysfunctions |
| 03/08/2006 | EP1631297A2 Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents |
| 03/08/2006 | EP1631295A2 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer |
| 03/08/2006 | EP1631294A1 A method of treating an anxiety disorder |
| 03/08/2006 | EP1631293A2 Compounds, formulations, and methods for treating or preventing rosacea |
| 03/08/2006 | EP1631291A2 Use of tyrosine kinase inhibitors to treat diabetes |
| 03/08/2006 | EP1631290A2 Combination therapy for the treatment of neoplasms |
| 03/08/2006 | EP1631289A2 Anti-hiv benzamide compounds |
| 03/08/2006 | EP1631288A1 Positive modulators of nicotinic acetylcholine receptors |
| 03/08/2006 | EP1631287A2 Novel long-acting medicament combinations comprising an anticholinergic agent and a $g(b)2-adrenoreceptor antagonist for the treatment of respiratory tract diseases |
| 03/08/2006 | EP1631286A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 03/08/2006 | EP1631285A1 Therapeutic agents useful for treating pain |
| 03/08/2006 | EP1631284A2 Solid-state forms of 5-(difluoromethoxy)-2-((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole (pantoprazole) sodium aqua complexes |
| 03/08/2006 | EP1631283A1 Antiarthritic combinations |
| 03/08/2006 | EP1631282A1 Use of the hydrochloride of the active ingredient base 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine combined with sumatriptan for the treatment of migraines |
| 03/08/2006 | EP1631281A2 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
| 03/08/2006 | EP1631280A1 Use of triglyceride oils containing gamma-linolenic acid residues and linoleic acid residues for the treatment of a neurodegenerative disease |
| 03/08/2006 | EP1631279A2 Combination therapy for the treatment of neoplasms |
| 03/08/2006 | EP1631278A1 Combination chemotherapy comprising capecitabine and a liposomal platinum complex |
| 03/08/2006 | EP1631277A1 Natural semi-synthetic and synthetic lipid derivatives of ceramide and sphingosine groups, drugs and the medical use thereof in the form of therapeutic agents in particular for dermatology |
| 03/08/2006 | EP1631276A2 Compositions for the enhanced treatment of depression |
| 03/08/2006 | EP1631275A1 Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
| 03/08/2006 | EP1631274A2 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| 03/08/2006 | EP1631273A1 Memantine oral dosage forms |
| 03/08/2006 | EP1631272A2 Methods of treating obesity and related disorders using tellurium and selenium compounds |
| 03/08/2006 | EP1631271A2 Methods and compositions for delivery of catecholic butanes for treatment of tumors |
| 03/08/2006 | EP1631270A2 Methods and compositions for delivery of catecholic butanes for treatment of diseases |
| 03/08/2006 | EP1631269A2 Methods and compositions for delivery of catecholic butanes for treatment of obesity |
| 03/08/2006 | EP1631268A2 Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure |
| 03/08/2006 | EP1631267A2 Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites |
| 03/08/2006 | EP1631266A2 A method of treating degenerative disc disease |
| 03/08/2006 | EP1631265A2 Use of various agents for inhibiting fibrous adhesions |
| 03/08/2006 | EP1631260A2 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| 03/08/2006 | EP1631254A1 Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof |
| 03/08/2006 | EP1631253A1 Sublingual administration of non-steroidal anti-inflammatory pharmacological substances |
| 03/08/2006 | EP1631252A1 Method for producing a solid pharmaceutical composition |
| 03/08/2006 | EP1631251A1 Delayed release tablet with defined core geometry |
| 03/08/2006 | EP1631239A2 Pharmaceutical compositions comprising active vitamin d compounds |